Last reviewed · How we verify
sodium fluorescein
Sodium fluorescein is a fluorescent dye that absorbs light and emits fluorescence, allowing visualization of ocular structures and blood flow in diagnostic imaging.
Sodium fluorescein is a fluorescent dye that absorbs light and emits fluorescence, allowing visualization of ocular structures and blood flow in diagnostic imaging. Used for Diagnostic imaging in fluorescein angiography for evaluation of retinal and choroidal vasculature, Assessment of retinal vascular diseases including diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion, Evaluation of anterior segment structures and corneal integrity.
At a glance
| Generic name | sodium fluorescein |
|---|---|
| Also known as | Fluorescein, Fluorocyte, AK-Fluor, Fluorescite |
| Sponsor | University Hospitals Cleveland Medical Center |
| Drug class | Diagnostic fluorescent dye |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Sodium fluorescein is a small-molecule fluorescent tracer that binds minimally to plasma proteins and rapidly distributes through the vasculature. When excited by blue light (typically 488 nm), it emits green fluorescence (510 nm), enabling real-time visualization of retinal and choroidal blood flow patterns, vascular leakage, and structural abnormalities in fluorescein angiography and other ophthalmic imaging modalities.
Approved indications
- Diagnostic imaging in fluorescein angiography for evaluation of retinal and choroidal vasculature
- Assessment of retinal vascular diseases including diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion
- Evaluation of anterior segment structures and corneal integrity
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
- Allergic reaction (rash, urticaria)
- Anaphylaxis
Key clinical trials
- A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer (NA)
- Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (PHASE4)
- Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE2)
- Automated Applanation Tonometry - Updated (NA)
- Retinal Vessel Leakage in Cerebral Small Vessel Disease
- Neoadjuvant Tebentafusp for Uveal Melanoma (PHASE2)
- Prevention of Onset and Transition to an Advanced Form of Diabetic Retinopathy in Children (NA)
- Intraoperative Use of I.V. Sodium Fluorescein in Suspected CNS Tumors
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sodium fluorescein CI brief — competitive landscape report
- sodium fluorescein updates RSS · CI watch RSS
- University Hospitals Cleveland Medical Center portfolio CI